Talphera (TLPH) vs. Its Competitors Financial Comparison

Talphera (NASDAQ:TLPHGet Free Report) is one of 977 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Talphera to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.


This table compares Talphera and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Talphera N/A -81.54% -46.02%
Talphera Competitors -1,989.66% -235.40% -30.48%

Earnings & Valuation

This table compares Talphera and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Talphera $1.77 million $47.76 million -0.49
Talphera Competitors $8.88 billion $178.56 million -1.58

Talphera’s rivals have higher revenue and earnings than Talphera. Talphera is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Talphera and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talphera 0 0 1 0 3.00
Talphera Competitors 5972 17676 42173 875 2.57

Talphera currently has a consensus target price of $6.00, suggesting a potential upside of 445.45%. As a group, “Pharmaceutical preparations” companies have a potential upside of 78.12%. Given Talphera’s stronger consensus rating and higher probable upside, equities analysts clearly believe Talphera is more favorable than its rivals.

Insider & Institutional Ownership

19.8% of Talphera shares are owned by institutional investors. Comparatively, 39.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.0% of Talphera shares are owned by company insiders. Comparatively, 14.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Talphera has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Talphera’s rivals have a beta of 0.78, indicating that their average share price is 22% less volatile than the S&P 500.


Talphera rivals beat Talphera on 7 of the 13 factors compared.

Talphera Company Profile

(Get Free Report)

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.

Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.